Iconovo, which said earlier this year that it would discontinue internal development and would focus on commercialization of its existing DPI platforms, has announced that CEO Johan Wäborg will step down, and advisor Anders Månsson will step in as interim CEO. The company’s dry powder inhaler platforms include the ICOres reservoir-based DPI, the ICOpre generic version of Ellipta, and the ICOone single use device. Wäborg had served as CEO of Iconovo since 2020.
The company said that in addition to experience as an executive at various pharma companies, Månsson “has also worked as an advisor to venture capital firms and consulting companies and has extensive and relevant experience from international business development and commercialization, which the Board considers especially valuable in the current phase of the company’s development.”
Iconovo Chairman of the Board Carl Lindgren commented, “I would like to thank Johan for his time at Iconovo, during which he, together with the company’s management team, led the work to complete the development of five unique and competitive inhalation platforms with great market potential. Now it is time to move forward and focus on business development and commercialization, making this a natural timepoint for a leadership transition. With Anders’ background and expertise, the board is very pleased to have him on board for this mission.”
Read the Iconovo press release
